Galderma Launches Alastin Regenerative Skincare Brand Across Japan and Asia-Pacific Markets
Key Insights
Galderma has launched its premium regenerative skincare brand Alastin (search) in Taiwan, with upcoming launches in Japan, Singapore, and South Korea through September and November 2026.
The expansion follows recent launches in China and Australia, targeting the fast-growing JPAC medical aesthetics and dermatological skincare market.
Nine Alastin (search) products featuring TriHex Technology will be available, including peri-procedural support products and daily treatment formulations for collagen and elastin renewal.
Galderma has announced the launch of Alastin (search), its premium regenerative skincare brand, across the Japan and Asia Pacific (JPAC) region, marking a significant expansion of the company's dermatological skincare portfolio in one of the world's fastest-growing markets for medical aesthetics. The brand recently debuted in Taiwan and will soon launch in Japan, with regulatory approvals secured for market introductions in Singapore and South Korea planned for September and November 2026, respectively.
This regional expansion follows Alastin (search)'s recent launches in China and Australia and underscores Galderma's continued investment in JPAC, a region characterized by advanced skincare practices and rapid growth in injectable aesthetics. According to Galderma, the JPAC region is among the fastest-growing markets globally for medical aesthetics and dermatological skincare.
Addressing Integrated Skincare Demand
The Alastin (search) brand is designed to meet the increasing demand for integrated skincare solutions that support skin readiness, recovery, and long-term quality. The product line amplifies the skin's natural regenerative abilities, supporting recovery and enhancing the visible outcomes of in-demand aesthetic procedures such as energy-based device and injectable treatments.
Galderma's launch of Alastin (search) represents another example of the company's unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings.
Product Portfolio and Technology
Nine products will be available in the JPAC region, organized across several categories. The procedure support products include Skin Nectar and INhance, both formulated with TriHex Technology. The daily treatment portfolio features Rejuvenate products designed to support ongoing collagen and elastin renewal: Restorative Skin Complex with TriHex+, Restorative Eye Complex with TriHex Technology, and Restorative Neck Complex with TriHex Technology.
Additionally, targeted serums address specific skin concerns: C-RADICAL Defense, an antioxidant serum that protects against environmental stressors; A-LUMINATE Brightening Serum, which reduces the appearance of hyperpigmentation and discoloration for a more even skin tone; and HA IMMERSE Serum, which enhances skin hydration. The daily care line includes Ultra Nourishing Moisturizer with TriHex Technology to help moisturize, nourish, and soothe skin.
The expansion across Taiwan, Japan, Singapore, and South Korea positions Galderma to capture growing demand in the Asia-Pacific region, where consumers increasingly seek peri-procedural skincare regimens that complement aesthetic treatments and support long-term dermatological health.